Nanosphere — Investor Presentation (October 2014)
24 slides from Nanosphere's investor presentation, Oct 21, 2014
Slide 1: Company Overview
Exhibit 99.2 COMPANY OVERVIEW OCTOBER 2014
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NANOSPHERE Thispresentationcontainsforward-lookingstatementsabout usandour industrythat involvesubstantialrisksanduncertainties.We intend suchforward-lookingstatementsto be coveredby the safeharbor provisionsfor forward-lookingstatementscontainedin Section21Eof the Securit
Slide 3: Investment Thesis
INVESTMENT THESIS NANOSPHERE Nanosphere • Proprietary high value tests that enable clinicians to rapidly identify some of the most complex, costly and deadly infectious diseases • Installed and growing customer base with leading hospital-based laboratories and academic research institutions in the U
Slide 4: Company Background
COMPANY BACKGROUND NANOSPHERE State of the Art Molecular Diagnostic Testing • Rapid viral and bacteria disease detection • Proprietary Verigene® System platform installed in over 250 U.S. hospitals and labs • Expanding menu of tests • Licensing relationship with the International Institute for Nanot
Slide 5: Our Mission
OUR MISSION NANOSPHERE Enhance Medicine Through Targeted Diagnostics • Improve Patient Care o Save lives o Decrease morbidity o Reduce spread of antibiotic resistance • Lower Costs to the Healthcare System o Shorter length of stay o Antibiotic savings o Demonstrated economic outcomes • Deliver Excep
Slide 6: Management Team
MANAGEMENT TEAM NANOSPHERE Officer / Title Background Joined Nanosphere in 2005 Michael McGarrity 13 years with Stryker Corporation President and Most recently Vice President, Stryker Instruments, a $700 million division of Stryker Chief Executive Officer Corporation Graduate of the University of No
Slide 7: Our State-of-the-Art Solution
OUR STATE-OF-THE-ART SOLUTION NANOSPHERE The Verigene System utilizes advanced automation, microfluidics and proprietary chemistry to enable rapid direct detection of nucleic acids and high-sensitivity protein detection on the same platform Current Verigene Platform Next Generation Verigene System (
Slide 8: Strong Patent Protection
STRONG PATENT PROTECTION NANOSPHERE Proprietary Technology Patents Our proprietary technology is based on and As of September 2014, our patent portfolio was exclusively licensed from the is comprised, on a worldwide basis, of over International Institute for Nanotechnology 180+ issued patents and 6
Slide 9: Highly Versatile Technology
HIGHLY VERSATILE TECHNOLOGY NANOSPHERE One To Detect For Multiple Applications Technology Multiple Analytes and Markets Diagnostics | Drug Development | Life Sciences DNA Gold nanoparticle 1) Multiplexed nucleic acid panels RNA — Infectious diseases — Human genetics, personalized medicine Proteins —
Slide 10: Multiplex MDx Market
MULTIPLEX MDX MARKET NANOSPHERE Key Points Total Addressable Market Total global addressable market Total Addressable Market x Penetrated for multiplex MDx applications is in ($Millions) US OUS WW x YE 2013 excess of approximately $1.1 billion Installed Base Hospital, Reference Labs 5,500 5,000 10,5
Slide 11: Expanding Menu of High Value Microbiology Tests
EXPANDING MENU OF HIGH VALUE MICROBIOLOGY TESTS NANOSPHERE Regulatory Status FDA Est. Annual Addressable Approval Revenue Per Market Menu FDA CE IVD Date Customer ($mm)(2) BSI —Gram Positive (BC-GP) June 2012 $50,000 $220 BSI —Gram Negative (BC-GN) January 2014 $30,000 80 Blood Culture Yeast (BC-Y)
Slide 12: Main Drivers of MDx Adoption
MAIN DRIVERS OF MDX ADOPTION NANOSPHERE Quicker Increased Response Capability Need Need for more timely Need to address and cost-effective costly and complex results disease states Product Sample- High Count Multi- Feature To-Result Plexing We believe that conversion of traditional culture-based met
Slide 13: Verigene Changes the Game in Sepsis
VERIGENE CHANGES THE GAME IN SEPSIS NANOSPHERE Rapid and accurate identification of infection-causing bacteria and resistance to commonly used antibiotics that enable clinicians to prescribe the right therapy at the right time Large Market With Unmet Need The Verigene Value Proposition Sepsis is a l
Slide 14: Verigene Impact
VERIGENE IMPACT NANOSPHERE Traditional Blood Culture Workflow The traditional blood culture workflow provides identification and resistance information at >48 hours Blood Culture Culture Samples Plated for Sub-Culture Resistance Testing and Gram Stain Results Hours 12 15 24 48 Verigene Workflow The
Slide 15: Verigene Benefits
VERIGENE BENEFITS NANOSPHERE Saves Last Line Saves Money Therapies Saves Lives Recent study by UF Shands: Banner Healthcare: Appropriate antibiotic 80% reduction in 21.7 day reduction in treatment reduced by I.C.U. mortality Length of stay/patient 40.3 hours and moved from 47.8% from prophylactic to
Slide 16: Migration of Antibacterial Resistance
MIGRATION OF ANTIBACTERIAL RESISTANCE NANOSPHERE Source: M. McKenna. Nature. Vol 499. 25 July 2013. 16
Slide 17: CDC Landmark Recommendations
CDC LANDMARK RECOMMENDATIONS NANOSPHERE • Burden and Threat Posed by Antibiotic-Resistant • Four Core Actions Must Be Taken Infections o Avoid infections o Drug resistant infections are a threat to human and o Track infections economic health o Improve antibiotic stewardship and use o Overuse of ant
Slide 18: Competitive Advantages
COMPETITIVE ADVANTAGES NANOSPHERE Rapid Blood Culture Testing Benefits Versus BioFire Nanosphere direct detection (no PCR) provides for Reduce Mortality: Each hour that appropriate antimicrobial accuracy in both sensitivity and specificity required for treatment is delayed, a sepsis patient’s mortal
Slide 19: Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS NANOSPHERE Clinical, economic and workflow benefits to hospitals and laboratories Community-Acquired Diarrhea (Enteric) The Verigene Value Proposition Caused by consumption of contaminated food or water More sensitive than culture (detects ~3X as many containing bacterial
Slide 20: Conversion of Respiratory Market
CONVERSION OF RESPIRATORY MARKET NANOSPHERE The respiratory market has historically been characterized as crowded and price sensitive Only a portion of hospitals have adopted molecular respiratory testing methodologies Many of the molecular-using hospitals have two platforms because of the way clini
Slide 21: Overview of Commercial Presence
OVERVIEW OF COMMERCIAL PRESENCE NANOSPHERE Sales and marketing organization comprises geographically dispersed sales representatives and clinical support specialists as well as a centralized staff of market and product managers Direct in the United States Distribution in Western Europe, Japan and Ch
Slide 22: Revenue and Gross Profit
REVENUE AND GROSS PROFIT NANOSPHERE Key Points Revenue Consistent revenue growth driven by test sales We believed expanded menu will drive revenue growth acceleration Backlog of placements pending instrument sales is $7.8 million Gross margin expansion primarily driven by recent consumable manufactu
Slide 23: Low Risk Margin Expansion
LOW RISK MARGIN EXPANSION NANOSPHERE 2016 / 2017 Projected Margin Drivers: Royalties (patent expiration) Primarily volume (materials & overhead absorption) 2015 Projected Margin Drivers: Consumable cavitation, labor and reagents (1) (1) Includes royalties and license amortization. 23
Slide 24: Summary Investment Highlights
SUMMARY INVESTMENT HIGHLIGHTS NANOSPHERE Proprietary Multiplexed Molecular Platform Large Addressable Markets With Unmet Needs Differentiated, High Value Tests in Sepsis and GI Infections Diversified, Customer Base Momentum With Leading Hospitals Attractive Placement and Assay Pull-Through Trends Hi